IBT favourite Array updates trial results ahead of key FDA decision Array Biopharma (ARRY), a top ten holding for LSE-listed International Biotechnology Trust (IBT), has reported positive results from a safety lead-in phase of a pivotal trial of a triplet therapy comprising two of its drugs – binimetinib and encorafenib – with Merck KGaA’s Erbutix in BRAF mutant […]
Arix, Syncona and WPCT bank gains after Autolus “pops” on Nasdaq IPO Arix Bioscience (ARIX), Syncona (SYNC) and Woodford Patient Capital Trust (WPCT) should be able to record some sizeable NAV gains this month, as previously highlighted in earlier Quoteddata.com articles, on the back of a revaluation to market value of their respective holdings in the common portfolio […]
US biotech IPO market faces key test after record five pricings The currently buoyant US market for biotech new issues faces a key test, after a record five companies priced Nasdaq offerings in a single day. The success of those listings in the immediate after-market is likely to be important gauge of the overall health […]
Syncona accelerates investment in gene therapy portfolio LSE-listed biotech VC fund Syncona (SYNC) has made a significant investment in three of its portfolio companies involved in developing gene therapies, with staged commitments of £85m ($112m) to Freeline Therapeutics, $35m to SwanBio and $12m to Orbit Biomedical. Freeline, which was spun out from University College London (UCL) in 2015, is […]
Alexion files for key drug with priority review voucher Trust favourite Alexion Pharmaceuticals (Nasdaq: ALXN) yesterday confirmed it had made a US regulatory submission for approval of ALXN1210, its long-acting C5 complement inhibitor, for the treatment of the ultra-rare condition of paroxysmal nocturnal hemoglobinuria (PNH). Alexion is a cornerstone holding for both the OrbiMed-managed Biotech Growth Trust […]
WPCT still at bottom of bio specialist trust league in May Neil Woodford’s eponymous Patient Capital Trust (WPCT) has once again ranked at the bottom of the performance league table of biotech/healthcare specialist investment trusts maintained by Marten & Co in the month of May, both in terms of price and NAV total return. This is […]
Arix, Syncona and WPCT look set to reap gains on pending Autolus Nasdaq IPO Three LSE-listed health/biotech venture capital investment firms – Arix Bioscience (ARIX), Syncona (SYNC) and Woodford Patient Capital Trust (WPCT) – should see a nice boost to their NAV if Autolus, the UK-based CAR-T cell company completes its proposed Nasdaq IPO. Autolus is a portfolio company for […]
FDA fast track review for trust-backed Sage Therapeutics Sage Therapeutics (Nasdaq: SAGE), a high conviction idea for two of the biotech sector specialist investment trusts, has confirmed that the US FDA has accepted the NDA filing for its lead product, brexanolone IV for treatment of postpartum (post natal) depression (PPD), and granted the application priority review status. NDA […]
Trust favourite Genmab hit by trial setback Denmark’s Genmab, a widely-held stock among the sector specialist investment trusts, has suffered a major setback in the past week with failure/termination of studies involving its lead product Darzalex, which is sold by Johnson & Johnson. The studies were both aimed at expanding the range of uses of Darzalex, […]
Biotech Growth blames large caps for 2017/18 under-performance OrbiMed-managed Biotech Growth Trust (BIOG) blamed an overweight position in large cap stocks for under-performance against the benchmark Nasdaq Biotechnology index (NBI) in the six months to March 2018 and financial year as a whole, having recorded a 6.7% fall in NAV against a 2.2% fall for […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated